The future of antibiotics begins with discovering new combinations
Antibiotic resistance is a worldwide and growing clinical problem. With limited drug development in the antibacterial space, combination therapy has emerged as a promising strategy to combat multidrug-resistant bacteria. Antibacterial combinations can improve antibiotic efficacy and suppress antibac...
| Main Authors: | , , , , |
|---|---|
| 其他作者: | |
| 格式: | 文件 |
| 语言: | English |
| 出版: |
Wiley
2021
|
| 在线阅读: | https://hdl.handle.net/1721.1/136148 |
| _version_ | 1826191465239281664 |
|---|---|
| author | Zhu, Meilin Tse, Megan W Weller, Juliane Chen, Julie Blainey, Paul C |
| author2 | Massachusetts Institute of Technology. Department of Biological Engineering |
| author_facet | Massachusetts Institute of Technology. Department of Biological Engineering Zhu, Meilin Tse, Megan W Weller, Juliane Chen, Julie Blainey, Paul C |
| author_sort | Zhu, Meilin |
| collection | MIT |
| description | Antibiotic resistance is a worldwide and growing clinical problem. With limited drug development in the antibacterial space, combination therapy has emerged as a promising strategy to combat multidrug-resistant bacteria. Antibacterial combinations can improve antibiotic efficacy and suppress antibacterial resistance through independent, synergistic, or even antagonistic activities. Combination therapies are famously used to treat viral and mycobacterial infections and cancer. However, antibacterial combinations are only now emerging as a common treatment strategy for other bacterial infections owing to challenges in their discovery, development, regulatory approval, and commercial/clinical deployment. Here, we focus on discovery-where the sheer scale of combinatorial chemical spaces represents a significant challenge-and discuss how combination therapy can impact the treatment of bacterial infections. Despite these challenges, recent advancements, including new in silico methods, theoretical frameworks, and microfluidic platforms, are poised to identify the new and efficacious antibacterial combinations needed to revitalize the antibacterial drug pipeline. |
| first_indexed | 2024-09-23T08:56:35Z |
| format | Article |
| id | mit-1721.1/136148 |
| institution | Massachusetts Institute of Technology |
| language | English |
| last_indexed | 2024-09-23T08:56:35Z |
| publishDate | 2021 |
| publisher | Wiley |
| record_format | dspace |
| spelling | mit-1721.1/1361482023-10-05T19:28:34Z The future of antibiotics begins with discovering new combinations Zhu, Meilin Tse, Megan W Weller, Juliane Chen, Julie Blainey, Paul C Massachusetts Institute of Technology. Department of Biological Engineering Massachusetts Institute of Technology. Microbiology Graduate Program Koch Institute for Integrative Cancer Research at MIT Antibiotic resistance is a worldwide and growing clinical problem. With limited drug development in the antibacterial space, combination therapy has emerged as a promising strategy to combat multidrug-resistant bacteria. Antibacterial combinations can improve antibiotic efficacy and suppress antibacterial resistance through independent, synergistic, or even antagonistic activities. Combination therapies are famously used to treat viral and mycobacterial infections and cancer. However, antibacterial combinations are only now emerging as a common treatment strategy for other bacterial infections owing to challenges in their discovery, development, regulatory approval, and commercial/clinical deployment. Here, we focus on discovery-where the sheer scale of combinatorial chemical spaces represents a significant challenge-and discuss how combination therapy can impact the treatment of bacterial infections. Despite these challenges, recent advancements, including new in silico methods, theoretical frameworks, and microfluidic platforms, are poised to identify the new and efficacious antibacterial combinations needed to revitalize the antibacterial drug pipeline. 2021-10-27T20:31:05Z 2021-10-27T20:31:05Z 2021-07 2021-08-25T16:35:31Z Article http://purl.org/eprint/type/JournalArticle https://hdl.handle.net/1721.1/136148 en 10.1111/nyas.14649 Annals of the New York Academy of Sciences Creative Commons Attribution NonCommercial License 4.0 https://creativecommons.org/licenses/by-nc/4.0/ application/pdf Wiley Wiley |
| spellingShingle | Zhu, Meilin Tse, Megan W Weller, Juliane Chen, Julie Blainey, Paul C The future of antibiotics begins with discovering new combinations |
| title | The future of antibiotics begins with discovering new combinations |
| title_full | The future of antibiotics begins with discovering new combinations |
| title_fullStr | The future of antibiotics begins with discovering new combinations |
| title_full_unstemmed | The future of antibiotics begins with discovering new combinations |
| title_short | The future of antibiotics begins with discovering new combinations |
| title_sort | future of antibiotics begins with discovering new combinations |
| url | https://hdl.handle.net/1721.1/136148 |
| work_keys_str_mv | AT zhumeilin thefutureofantibioticsbeginswithdiscoveringnewcombinations AT tsemeganw thefutureofantibioticsbeginswithdiscoveringnewcombinations AT wellerjuliane thefutureofantibioticsbeginswithdiscoveringnewcombinations AT chenjulie thefutureofantibioticsbeginswithdiscoveringnewcombinations AT blaineypaulc thefutureofantibioticsbeginswithdiscoveringnewcombinations AT zhumeilin futureofantibioticsbeginswithdiscoveringnewcombinations AT tsemeganw futureofantibioticsbeginswithdiscoveringnewcombinations AT wellerjuliane futureofantibioticsbeginswithdiscoveringnewcombinations AT chenjulie futureofantibioticsbeginswithdiscoveringnewcombinations AT blaineypaulc futureofantibioticsbeginswithdiscoveringnewcombinations |